Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TACE is an oral small-molecule capsule in pre-launch development by Sanofi with a remarkably broad indication portfolio spanning oncology (hepatocellular carcinoma, leukemias, lymphomas, myeloma), autoimmune/inflammatory diseases (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, lupus), and transplant medicine. The mechanism of action and exact pharmacologic class are undisclosed, but the indication breadth suggests potential immunomodulatory or multi-targeted kinase activity. This pre-launch NDA candidate represents either a pivotal platform asset or a data-collection exercise across multiple therapeutic areas.
Growth
Pre-launch stage signals active brand-building, market access strategy, and manufacturing scale-up; teams likely growing across medical, commercial, and operations functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
Started Mar 2026
40 enrolled
HCC - Hepatocellular Carcinoma
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Started Mar 2026
105 enrolled
Hepato Cellular Carcinoma (HCC)
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
Started Nov 2025
300 enrolled
Hepatocellular Carcinoma
TACE Treats Nodular Goiter
Started Sep 2025
30 enrolled
Nodular Goiter
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Started Apr 2025
24 enrolled
Hepatocellular Carcinoma (HCC)Unresectable Hepatocellular Carcinoma
Worked on TACE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.